TY - JOUR
T1 - Comparison of growth rate of two B16 melanomas differing in metastatic potential in young versus middle-aged mice
AU - Donin, Natalie
AU - Sinai, Judith
AU - Staroselsky, Alexander
AU - Mahlin, Tatiana
AU - Nordenberg, Jardena
AU - Leibovici, Judith
N1 - Funding Information:
This study was supported by the Schauder Fund for Medical Research. Dr. Natalie Donin is supported by the Ministry of Absorption, Israel.
PY - 1997
Y1 - 1997
N2 - The rise of cancer frequency as a function of age is a well-established fact. The aspect of the host age-tumor progression relationship, namely the slower metastatic spread in aged patients, has been investigated to a lesser extent. In the present study, we examined whether host-age-dependent growth rate varies with metastatic capacity of the tumor. The parental B16 and the B16/Col/R, a highly metastatic variant, were employed. A more pronounced growth of both tumors in young as compared to middle-aged mice was found. However, the differential growth in middle-aged versus young mice was more evident in the highly metastatic variant. According to the tumor size data, a sixfold growth reduction in middle-aged mice was observed with B16/Col/R and an only twofold growth reduction was seen with the B16 melanoma. The data might eventually contribute to the finding of more appropriate treatment modalities for the middle-aged cancer patient.
AB - The rise of cancer frequency as a function of age is a well-established fact. The aspect of the host age-tumor progression relationship, namely the slower metastatic spread in aged patients, has been investigated to a lesser extent. In the present study, we examined whether host-age-dependent growth rate varies with metastatic capacity of the tumor. The parental B16 and the B16/Col/R, a highly metastatic variant, were employed. A more pronounced growth of both tumors in young as compared to middle-aged mice was found. However, the differential growth in middle-aged versus young mice was more evident in the highly metastatic variant. According to the tumor size data, a sixfold growth reduction in middle-aged mice was observed with B16/Col/R and an only twofold growth reduction was seen with the B16 melanoma. The data might eventually contribute to the finding of more appropriate treatment modalities for the middle-aged cancer patient.
UR - http://www.scopus.com/inward/record.url?scp=0030853588&partnerID=8YFLogxK
U2 - 10.3109/07357909709047580
DO - 10.3109/07357909709047580
M3 - ???researchoutput.researchoutputtypes.contributiontojournal.article???
C2 - 9316623
AN - SCOPUS:0030853588
SN - 0735-7907
VL - 15
SP - 416
EP - 421
JO - Cancer Investigation
JF - Cancer Investigation
IS - 5
ER -
